Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053677 | 0.82 | TSHR (0.37) | ALDH1A1POLBHTTSMN1; SMN2TSHR | |
| SCHEMBL6322610 | 0.80 | PRMT5 (0.47) | ALDH1A1HTTSMN1; SMN2TSHRKMT2A | |
| SCHEMBL7678472 | 0.79 | ALDH1A1 (0.43) | ALDH1A1POLBHTTSMN1; SMN2TSHR | |
| SCHEMBL29524977 | 0.79 | ALDH1A1 (0.41) | ALDH1A1POLBHTTSMN1; SMN2TSHR | |
| SCHEMBL158497 | 0.77 | TSHR (0.55) | ALDH1A1POLBHTTSMN1; SMN2TSHR | |
| SCHEMBL11643646 | 0.76 | ALDH1A1 (0.44) | ALDH1A1POLBHTTSMN1; SMN2TSHR | |
| SCHEMBL3150494 | 0.76 | CA2 (0.39) | ALDH1A1POLBHTTSMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL27776511 | 0.76 | TSHR (0.53) | ALDH1A1POLBHTTSMN1; SMN2TSHR | |
| SCHEMBL27546731 | 0.75 | LMNA (0.35) | ALDH1A1POLBCHRM2CHRM4CHRM1 | |
| SCHEMBL8720475 | 0.75 | ALDH1A1 (0.40) | ALDH1A1POLBHTTSMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188043-A | Tetracyclic compound | 梅迪维新技术公司 | 2016-12-07 | — | — | CN | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES INC. | 2013-08-08 | — | — | US | disclosed |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8338408-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2217598-A1 | NEW TETRACYCLIC COMPOUNDS | Medivation Technologies, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
| WO-2009055828-A1 | NEW TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | ALDH1A1 1557/4885POLB 4782/4885HTT 84/4885 |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | ALDH1A1 1557/4885POLB 4782/4885HTT 84/4885 |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | ALDH1A1 1557/4885POLB 4782/4885HTT 84/4885 |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | ALDH1A1 1557/4885POLB 4782/4885HTT 84/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | ALDH1A1 1557/4885POLB 4782/4885HTT 84/4885 |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | ALDH1A1 1557/4885POLB 4782/4885HTT 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.